Frequency of antiphospholipid antibodies and factor V (G1691A), prothrombin (G20210A) gene polimorphism among women with pregnancy complications;Czȩstość wystȩpowania przeciwciał antyfosfolipidowych oraz polimorfizmu genów czynnika V (G1691A) i protrombiny (G20210A) u kobiet z nieprawidłowym przebiegiem cia̧ży

Polskie Archiwum Medycyny Wewnetrznej

Volumn 115, Issue 5, 2006, Pages 417-425

  Rajewski, Marcin ^a,b   Skrzypczak, Jana ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b NONE   (Poland)

Author keywords

Antiphospholipid syndrome; Factor V and prothrombin gene polimorphism; Pregnancy complications; Thrombophilia; Venous and arterial thromboembolism

Indexed keywords

BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 5; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN;

ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; POLYMERASE CHAIN REACTION; PREGNANCY COMPLICATION; RISK ASSESSMENT; SCREENING; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; ACTIVATED PROTEIN C RESISTANCE; ADULT; BLOOD; COMORBIDITY; GENETICS; MUTATION; POLAND; PREGNANCY; PREGNANCY OUTCOME; PREVALENCE; REFERENCE VALUE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SPONTANEOUS ABORTION;

ABORTION, SPONTANEOUS; ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; COMORBIDITY; FACTOR V; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; MUTATION; POLAND; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; PREVALENCE; PROTHROMBIN; REFERENCE VALUES; RISK FACTORS; THROMBOPHILIA;

EID: 33749137255     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Franco R. Analysis of the 677 CT mutation of the MTHFR gene in different ethnic groups. Thrombosis and Haemostasis. 1998; 77: 466-471.
2. Uszyński M. Położnicze aspekty trombofilii wrodzonej: epidemiologia i patomechanizm powikłań położnicznych oraz zapobieganie tym powikłaniom. Gin Pol., 2003; 74: 398-411.
3. Coulam C.B. Interlaboratory inconsistencies in detection of anticardiolipin antibodies. Lancet. 1990; 335: 865.
4. Galli M. Antipphospholipid antibodies and thrombosis: do test patterns identify the patients' risk? Thromb Research. 2004; 114: 597-601.
5. Rees D. World distribution of factor V Leiden. Lancet. 1995; 346: 1133-1134.
6. Foka Z.J. Factor V Leiden and prothrombin G20210A mutation, but not MTHFR C677T, are associated with recurrent miscarriages. Hum Reprod. 2000; 15: 458-462.
7. Rosendaal F. Geographic distribution of the 20210 G to A prothrombin variant. Thrombosis and Haemostasis. 1998; 79: 706-708.
8. Tall J. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod. 1999;14: 1624-1627.
9. Stone S. Placentation, antiphospholipid syndrome and pregnancy outcome. Lupus. 2001; 10: 67.
10. Kupferminc M.J. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Eng J Med. 1999; 340: 9-13.
11. Greeves M. National Screening Comitee: Workshop on screening for late onset genetic disorders-heritable thrombophilia. December. 13, 2000.
12. Blumenfeld Z. Thrombophilia associated pregnancy wastage. Fertil Steril. 1999; 72: 765-774.
13. Brenner B. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Throm Haemost. 2000; 83: 693-697.
14. Zotz R.B. Prediction, prevention and treatment of venous thromboembolic disease in pregnancy. A review. Semin Thromb Haemost. 2003; 29: 143-154.
15. Alfirevic Z. Postnatal screening for thrombophilia in women with severe pregnancy complications. Obstet Gynecol. 2001; 97: 753-759.
16. Dizon-Towson D.S. The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol. 1997; 34: 217-223.
17. Pauer H.U. Analyzes of three common thrombophilic gene mutations in German women with recurrent abortions. Acta Obstet Gynecol Scand. 2003; 82: 942-947.
18. Martinelli I. Mutations in coagulation factors in women with unexplained late fetal loss. N Eng J Med. 2000; 343: 1015-1018.
19. Rai R. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod. 2001; 16: 519-524.
20. Sarig G. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fert Steril. 2002; 77: 342-347.
21. Brenner B. Inherited thrombophilia and fetal loss. Curr Opin Hematol. 2000; 7, 290-295.
22. Kutteh W., Ermel L. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol. 1996; 35: 402-407.
23. Clark P. Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet, 2002; 359: 1919-1920.
24. Gris J. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004; 103: 3695-3699.
25. Pattison N. Does aspirin have a role in improving pregnancy outcome for women with antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol. 2000; 183, 1008-1012.